1. Very good partial response in a patient with MALT-lymphoma of the lung after treatment with low-dose thalidomide
- Author
-
Heinz Gisslinger, Andreas Chott, Markus Raderer, Mathias Kees, and Sylvia Metz-Schimmerl
- Subjects
Male ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,medicine.medical_treatment ,Gastroenterology ,immune system diseases ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Very Good Partial Response ,Chemotherapy ,Lung ,business.industry ,Low dose ,MALT lymphoma ,Hematology ,Lymphoma, B-Cell, Marginal Zone ,Middle Aged ,medicine.disease ,Surgery ,Thalidomide ,medicine.anatomical_structure ,Oncology ,Rituximab ,business ,Tomography, X-Ray Computed ,Rare disease ,medicine.drug - Abstract
Pulmonary MALT lymphoma is a rare disease entity and generally follows an indolent clinical course. Due to scarce information from randomized prospective trials, no standardized therapy protocols exist. Besides irradiation and chemotherapy, novel biological agents such as the anti CD20-antibody rituximab and thalidomide constitute a promising new approach. In this report we demonstrate the case of a 52-year-old male patient with extra-intestinal MALT lymphoma of the lung. After 10 months of treatment with low dose thalidomide (100mg/d), very good partial response of the intrapulmonary lesions was achieved.
- Published
- 2005